Curated News
By: NewsRamp Editorial Staff
June 02, 2026

Quantum BioPharma's Lucid-MS Targets MS Mobility Loss on BioMedWire Podcast

Discuss on Substack Discuss on Telegram
Original Source

TLDR

  • Quantum BioPharma's Lucid-MS targets mobility loss in MS, a large unmet market, and Phase 2 trial could set it apart.
  • Lucid-MS aims to reverse myelin degradation, shown in preclinical models, with Phase 2 trial upcoming in MS patients.
  • Quantum BioPharma's therapy could restore mobility for MS patients, significantly improving quality of life and independence.
  • Quantum also sells unbuzzd, a product that speeds alcohol metabolism, and earns royalties on its sales.

Impact - Why it Matters

This news matters because multiple sclerosis affects over 2.8 million people worldwide, and current treatments often fail to address mobility loss caused by nerve damage. Quantum BioPharma's Lucid-MS aims to fill this gap by targeting myelin degradation, potentially improving quality of life for patients. Additionally, the company's unbuzzd(TM) product offers a novel approach to alcohol metabolism, which could have broader public health implications. The upcoming Phase 2 trial will provide crucial data on Lucid-MS's efficacy, making this a pivotal moment for both the company and MS patients.

Summary

Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) was featured on the latest episode of The BioMedWire Podcast, where co-founder Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS. This therapy aims to address mobility loss associated with multiple sclerosis (MS) by targeting nerve damage, an area Durkacz believes remains unmet by current treatments. The company is preparing for a Phase 2 clinical trial for Lucid-MS, which will be the first study to evaluate the drug in MS patients after Phase 1 testing in healthy volunteers.

Beyond its MS pipeline, Quantum BioPharma has commercialized a product called unbuzzd(TM), which accelerates blood alcohol metabolism and is already available in the U.S. market. The company retains a 19.84% stake in Unbuzzd Wellness Inc., which markets the OTC version, and also receives royalty payments: 7% of sales until $250 million is reached, then 3% in perpetuity. Quantum retains full rights to develop similar formulations for pharmaceutical and medical uses.

Durkacz emphasized that Lucid-MS could be a game-changer for MS patients, as it targets myelin degradation, the underlying mechanism of the disease, potentially preventing and reversing damage. The company is also exploring applications for other neurodegenerative and metabolic disorders. Investors can follow updates in QNTM newsroom.

Source Statement

This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Quantum BioPharma's Lucid-MS Targets MS Mobility Loss on BioMedWire Podcast

blockchain registration record for this content.